KEYTRUDA (pembrolizumab) as Monotherapy Significantly Improved Progression‑Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
In patients with mismatch‑repair‑deficient (dMMR) advanced or recurrent endometrial cancer who have not previously received systemic chemotherapy, KEYTRUDA monotherapy significantly improves progression‑free survival compared with platinum doublet chemotherapy.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Immunotherapy improves endometrial cancer outcomes
- Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials
- Endometrial Cancer - PMC
- Current recommendations and recent progress in endometrial cancer
- Advancements in Endometrial Cancer Research in 2024